Acute Intermittent Porphyria With Seizure and Paralysis in the Puerperium

Yi-Kong Keung, MD, Temduang Chuahirun, MD, and Everardo Cobos, MD

Porphyrias are a group of metabolic disorders, usually genetic in origin, secondary to deficiencies of various enzymes involved in the heme biosynthetic pathways. They are usually classified into hepatic and erythropoietic types based on the major sites of the porphyrin production. It is more clinically useful, however, to classify this disorder into acute and nonacute types based on the clinical findings. Acute type includes the acute intermittent porphyria, variegate porphyria, and hereditary coproporphyria. The nonacute type includes the porphyria cutanea tarda and erythropoietic porphyrias.

Acute intermittent porphyria is the most severe form of the disease, with gastrointestinal and neuropsychiatric manifestations, such as abdominal pain, vomiting, peripheral neuropathy (motor, sensory, and autonomic), hypertension, seizures, depression, psychosis, and so on. Pregnancy complicating a known diagnosis of porphyria has been reported as early as in the 1950s. A first attack of acute porphyria with pregnancy is rare, however. This disease can be a diagnostic challenge to obstetricians and family physicians. It is important that physicians are alert to porphyria so they can make this diagnosis promptly, because proper management will dramatically improve the outcome in this otherwise debilitating and potentially life-threatening disease.

We describe a very rare case of acute intermittent porphyria in which the patient had a generalized seizure and progressive paralysis in the puerperium.

Case Report
A 20-year-old woman, gravida 2, para 2, had a generalized seizure and hypertension 3 days after an emergency cesarean delivery of her second child at 33 weeks' gestation complicated by pyelonephritis. She was given ciprofloxacin, phenytoin, and nifedipine. A computerized tomographic scan of the brain was normal. Magnetic resonance imaging of the brain showed two small, nonspecific demyelinating areas in the left posterior parietal region at the level of the lateral ventricle. There was no evidence of cerebral tumor, hemorrhage, or infarct. She was transferred to our hospital for management of her poorly controlled generalized seizure. At admission, the patient was lethargic, which was attributed to a phenytoin overdose of 33.9 μg/mL (therapeutic level 10 to 20 μg/mL). Her serum sodium was 119 mEq/L, potassium 3.1 mEq/L, chloride 79 mEq/L, bicarbonate 31 mEq/L, blood urea nitrogen 10 mg/dL, and creatinine 0.6 mg/dL. Alanine transaminase was 64 U/L, aspartate transaminase was 78 U/L, and alkaline phosphatase was 239 U/L. Study results of the serum and urine osmolarity were consistent with the syndrome of inappropriate antidiuretic hormone (SIADH).

Despite having her electrolyte abnormalities and phenytoin level corrected in the next few days, the patient remained lethargic, and her upper and lower limbs became progressively weaker. Her tendon reflexes were markedly decreased, but her plantar reflex was normal. Initially a consulting neurologist suggested a probable diagnosis of postpartum Guillain-Barre syndrome. Intravenous immunoglobulin and plasma exchange was started with no response. A subsequent nerve conduction study showed mildly prolonged latencies and reduced amplitude of the peroneal nerve. Conduction velocity was within normal limits.

Other causes of muscle weakness with hyporeflexia and preserved plantar reflex were sought. Analysis of her cerebrospinal fluid showed no white blood cells, her protein level was 63 mg/dL and glucose 56 mg/dL, and she had a nonreactive VDRL test. Her aldolase level was within normal limits; hence, myopathy was unlikely. Heavy-metal poisoning was considered as a cause of peripheral
neuropathy, but her blood mercury and lead levels were normal. Antinuclear antibody level was borderline at a low titer of 1:80. Lyme disease was unlikely after a negative test for Borrelia burgdorferi antibodies (enzyme-linked immunosorbent assay). Urine screening for porphobilinogen by the Watson-Schwartz test was positive. Subsequently 24-hour urine quantitation of porphobilinogen was 139.5 mg/24 h (normal ≤ 2.7 mg/24 h), δ-aminolevulinic acid 39 mg/24 h (normal ≤ 6.4 mg/24 h), uroporphyrin 1279.7 μg/24 h (normal 3.3–29.5 μg/24 h), and coproporphyrin 637.9 μg/24 h (normal ≤ 155 μg/24 h). Acute porphyria was confirmed. The patient was given a high-carbohydrate diet, and hematin, 4 mg/kg (Abbott Laboratories, Chicago), was given intravenously daily for 2 weeks. Her recovery of motor function was slow but definite. Although 1 year later she continues to have wrist and foot drop, she is ambulatory with ankle braces and is able to attend to her normal daily activities with wrist support.

Discussion

The many precipitating factors that are known to induce acute porphyria attacks in susceptible persons include hormonal changes associated with pregnancy and menstrual cycle, reduced caloric intake, drugs, stress, and infections. Barbiturates, sulphonamide, anticonvulsants, and oral contraceptives are by far the most common drugs implicated in acute porphyria. These conditions or medications directly or indirectly induce the δ-aminolevulinic acid synthase activity, which results in an increased biosynthesis of heme and the various intermediate porphyrins (Figure 1).

Pregnancy and its associated hormonal changes increase porphyrin metabolism and therefore can precipitate acute porphyria attacks. Nevertheless, our patient had an uneventful first pregnancy, and only after delivery of her second child was porphyria diagnosed. In Table 1, we summarize all reported cases of acute porphyria in which the initial attack was associated with pregnancies. In 10 of 14 cases the women had normal or apparently normal pregnancies before the initial diagnosis. Alternatively, the symptoms might have been so mild and nonspecific that the diagnosis was missed in previous pregnancies, as in case 6. In eight cases the patients were exposed to a known inciting agent or infection. This finding probably suggests that pregnancy alone might be insufficient to induce an attack. According to the study of pregnancy outcome in patients with known porphyria, the attack rate is only 16% in the antenatal period and 8% in puerperium.

We believe that the initial porphyria attack, which took the form of a generalized seizure and hypertension in our patient, occurred after cesarean delivery and probably was related to reduced caloric intake after surgery and pyelonephritis. The use of phenytoin and nifedipine to control her seizure and hypertension further aggravated the metabolic derangement, resulting in progressive motor neuropathy. In our patient severe hypotension and SIADH at diagnosis were probably due to the hypothalamic involvement of acute porphyria and the salt-losing state of pyelonephritis. The treatment of acute porphyria is high-caloric intake and hematin. The precise mechanism of high-caloric diet to abrogate acute porphyria attack is unclear. Increased glucose intake in animals has been shown, however, to repress the inducing effect of chemicals on δ-aminolevulinic acid synthase. Hematin, a derivative from processed red blood cells, is believed to inhibit δ-aminolevulinic acid synthase activity directly and hence decrease the production and accumulation of various porphyrins (Figure 1).

Another important differential diagnosis of progressive weakness associated with pregnancy is Guillain-Barré syndrome. A recent retrospective study of Guillain-Barré syndrome associated with pregnancy revealed that the risk tends to increase in the puerperium. The similar presenting features of both Guillain-Barré syndrome and acute porphyria and the equivocal findings of the nerve
Table 1. Summary of all Cases of Acute Intermittent Porphyria with Initial Attack Associated with Pregnancy.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (y), Gestational Age</th>
<th>Clinical Features</th>
<th>Inciting Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>25, G1P0, 12 weeks</td>
<td>Seizure, coma</td>
<td>Barbiturate</td>
</tr>
<tr>
<td>2</td>
<td>26, G1P0, 8 weeks</td>
<td>Vomiting, lethargy, paralysis</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>38, G2P2, Puerperium</td>
<td>Paroxysmal pain, hallucinations</td>
<td>Pseudonephritis</td>
</tr>
<tr>
<td>4</td>
<td>27, G3P2, 1st trimester</td>
<td>Abdominal pain</td>
<td>—</td>
</tr>
<tr>
<td>5</td>
<td>22, G12P11, 1st trimester</td>
<td>Epigastric pain, red urine</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>22, G4P2, 10 weeks</td>
<td>Recurrent abdominal pain associated with each pregnancy</td>
<td>—</td>
</tr>
<tr>
<td>7</td>
<td>23, G1P1, Puerperium</td>
<td>Epigastric pain, vomiting, slurred speech, personality changes</td>
<td>Barbiturate</td>
</tr>
<tr>
<td>8</td>
<td>16, G1P0, 32 weeks</td>
<td>Anemia, retrosternal pain, vomiting, SIADH</td>
<td>Barbiturate</td>
</tr>
<tr>
<td>9</td>
<td>21, G1P0, 29 weeks</td>
<td>Abdominal pain, vomiting, motor neuropathy</td>
<td>Sulfadiazine</td>
</tr>
<tr>
<td>10</td>
<td>27, G2P1, 10 weeks</td>
<td>Abdominal pain, mental changes, irritability, depression, motor neuropathy</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>11</td>
<td>29, G2P1, 1st trimester</td>
<td>Positive screening with family history</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>23, G2P1, 36 weeks</td>
<td>Mental changes, ataxia</td>
<td>—</td>
</tr>
<tr>
<td>13</td>
<td>29, G3P2, 13 weeks</td>
<td>Abdominal pain, vomiting, depression, hallucination, memory loss, irritability</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>Current</td>
<td>20, G2P2</td>
<td>Puerperium</td>
<td>Seizure, SIADH, and progressive quadriplegia</td>
</tr>
</tbody>
</table>

SIADH—syndrome of inappropriate antidiuretic hormone.

*None or not stated.

Conduction study have contributed to the initial misdiagnosis in our case. In retrospect, our patient’s mental symptoms, SIADH, and normal nerve conduction velocity probably speaks more for the diagnosis of acute porphyria.

Finally, we cannot emphasize more that a high index of suspicion is important to make the correct diagnosis of acute porphyria, because proper management will dramatically improve the outcome in this debilitating and potentially life-threatening disease.

References


78 JABFP January–February 2000 Vol. 13 No. 1
